Results 11 to 20 of about 239,525 (205)
Meningococcal glycoconjugate vaccines [PDF]
Human Vaccines, 2011 Neisseria meningitidis is a major cause of invasive bacterial infections worldwide. For this reason, efforts to control the disease have been directed at optimizing meningococcal vaccines and implementing appropriate vaccination policies.
GASPARINI, ROBERTO +3 more
core +3 more sources
Meningococcal vaccine evolution
Clinical Management Issues, 2012 Neisseria meningitidis is a leading cause of bacterial sepsis and meningitis worldwide. Although polysaccharide and glycoconjugate vaccines have been developed for serogroups A, C, Y and W-135, currently there are no broadly effective vaccines available ...
Gianni Bona, Carla Guidi
doaj +6 more sources
Meningococcal vaccination in pregnancy [PDF]
Human Vaccines & Immunotherapeutics, 2018 Invasive meningococcal disease causes meningitis and septicemia worldwide with highest rates of disease occurring in children
Bahaa Abu Raya, Manish Sadarangani
doaj +3 more sources
Challenges and opportunities for meningococcal vaccination in the developing world [PDF]
Human Vaccines & Immunotherapeutics, 2018 Meningococcal disease continues to be a life threatening infection with high morbidity and mortality even in appropriately treated patients. Meningococcal vaccination plays a major role in the control of the disease; however, implementing vaccination ...
Rouba Shaker +2 more
doaj +2 more sources
Meningococcal conjugate vaccines: optimizing global impact
Infection and Drug Resistance, 2011 Andrew Terranella1,2, Amanda Cohn2, Thomas Clark2 1Epidemic Intelligence Service, Division of Applied Sciences, Scientific Education and Professional Development Program Office, 2Meningitis and Vaccine Preventable Diseases Branch, National Center for ...
Terranella A, Cohn A, Clark T
doaj +1 more source
Meningococcal disease: changes in epidemiology and prevention
Clinical Epidemiology, 2012 Qiuzhi Chang,1 Yih-Ling Tzeng,2 David S Stephens1–31Department of Epidemiology, Rollins School of Public Health, Emory University, 2Department of Medicine, Emory University School of Medicine, 3Laboratories of Microbial Pathogenesis, Department
Chang Q, Tzeng YL, Stephens DS
doaj +1 more source
Impact of meningococcal group B OMV vaccines, beyond their brief
Human Vaccines & Immunotherapeutics, 2018 Meningococcal group B outer membrane vesicle vaccines have been used widely in Cuba, New Zealand, and Brazil. They are immunogenic and initially assessed largely by their ability to induce serum bactericidal activity.
Helen Petousis-Harris
doaj +2 more sources
Expert Review of Vaccines, 2002 The successful introduction of a protein-polysaccharide conjugate vaccine against serogroup C meningococci into the UK infant immunization schedule, in combination with a catch-up campaign for individuals less than 18 years of age, has seen virtually all group C disease eliminated in childhood.
Bethell, D, Pollard, A
openaire +4 more sources
Bacterial outer membrane vesicles and vaccine applications [PDF]
, 2014 Vaccines based on outer membrane vesicles (OMV) were developed more than 20 years ago against Neisseria meningitidis serogroup B. These nano-sized structures exhibit remarkable potential for immunomodulation of immune responses and delivery of “self ...
Jose Luis Perez +30 more
core +3 more sources
Pediatric Infectious Disease Journal, 2004 The 5 major pathogenic serogroups of the Gram-negative encapsulated bacterium Neisseria meningitidis are A, B, C, Y, and W135. In the 1960s, vaccines consisting of purified capsular polysaccharide antigens were developed against serogroups A, C, Y, and W135.
Rüggeberg, J, Pollard, A
openaire +6 more sources